28 completed, 2 active not recruiting, 2 unknown, 1 withdrawn. 18 Phase 2, 8 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 16, Unknown 2 |
| Phase 1 | 8 | Completed 6, Active not recruiting 2 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow Recurrent Uterine Corpus Carcinoma: new trials by email Literature Review of Recurrent Uterine Corpus Carcinoma trials Research Report on Recurrent Uterine Corpus Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 25 | 2018-07-12 | 2025-02-13 |
| Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 1 | Completed | City of Hope Medical Center | 44 | 2017-10-02 | 2026-10-01 |
| Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer Carboplatin, Enzalutamide, Laboratory Biomarker Analysis - Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 50 | 2016-08-24 | 2025-03-19 |
| Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer Laboratory Biomarker Analysis, Letrozole, Ribociclib - Estrogen Receptor Positive, Postmenopausal | Phase 2 | Completed | Mayo Clinic | 40 | 2016-07-08 | 2021-10-26 |
| Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies Palliative Therapy, Palliative Therapy + idiographic - Cervical Carcinoma, Ovarian Carcinoma | Not applicable | Completed | Albert Einstein College of Medicine | 95 | 2015-04-01 | 2019-09-17 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Capivasertib, Laboratory Biomarker Analysis, Olaparib - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 159 | 2014-11-11 | 2026-09-04 |
| Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer Carboplatin, Cisplatin, Gemcitabine Hydrochloride - FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer | Phase 1 | Active not recruiting | City of Hope Medical Center | 40 | 2014-07-01 | 2026-10-26 |
| Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 / Phase 3 | Unknown | Gynecologic Oncology Group | 469 | 2014-03-17 | 2021-09-30 |
| Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Dalantercept, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 28 | 2012-09-01 | 2018-03-13 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Nintedanib - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 37 | 2011-10-01 | 2017-10-09 |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Carboplatin, Dasatinib, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 18 | 2011-09-20 | 2018-04-05 |
| Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Trebananib - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 35 | 2011-06-06 | 2018-02-23 |
| Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Akt Inhibitor MK2206, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2011-03-01 | 2022-02-11 |
| Prognostic Biomarkers in Patients With Endometrial Cancer Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Recurrent Uterine Corpus Carcinoma | Completed | Gynecologic Oncology Group | 2824 | 2010-09-01 | 2017-08-23 | |
| Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer Medical Chart Review, Questionnaire Administration - Recurrent Cervical Carcinoma, Recurrent Uterine Corpus Carcinoma | Completed | Gynecologic Oncology Group | 778 | 2010-07-01 | 2018-04-12 | |
| Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Cediranib Maleate, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 53 | 2010-06-01 | 2019-08-08 |
| Biomarkers in Samples From Patients With Endometrial Cancer Laboratory Biomarker Analysis - Lynch Syndrome, Recurrent Uterine Corpus Carcinoma | Withdrawn | Gynecologic Oncology Group | 2010-01-01 | 2024-08-14 | ||
| Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Laboratory Biomarker Analysis - Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer | Completed | Gynecologic Oncology Group | 169 | 2010-01-01 | 2024-08-14 | |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Bevacizumab, Temsirolimus - Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 252 | 2009-09-08 | 2019-01-25 |
Showing 20 of 33. Sign in to see all of them.
Ovarian Neoplasms (10) · Fallopian Tube Neoplasms (7) · Breast Neoplasms (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Hepatocellular (2) · Melanoma (2) · Sarcoma, Endometrial Stromal (2) · Triple Negative Breast Neoplasms (2) · Vulvar Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Brenner Tumor (1) · Carcinoma, Endometrioid (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1)
Neoplasms (15) · Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Genital Diseases (14) · Genital Diseases, Female (14) · Genital Neoplasms, Female (14) · Neoplasms by Site (14) · Urogenital Diseases (14) · Urogenital Neoplasms (14) · Adnexal Diseases (11) · Endocrine System Diseases (11) · Gonadal Disorders (11) · Ovarian Diseases (11) · Endocrine Gland Neoplasms (10) · Fallopian Tube Diseases (7)
Paclitaxel (6) · Carboplatin (5) · Taxes (5) · Gemcitabine (4) · Cisplatin (3) · Doxorubicin (3) · Sirolimus (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Filgrastim (2) · Platinum (2) · mirvetuximab soravtansine (2) · pegfilgrastim (2) · temsirolimus (2) · ALK1-Fc fusion protein, human (1) · AZD 6244 (1)
Gynecologic Oncology Group (14) · National Cancer Institute (NCI) (10) · City of Hope Medical Center (2) · M.D. Anderson Cancer Center (2) · Albert Einstein College of Medicine (1) · GOG Foundation (1) · Mayo Clinic (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (31) · Canada (4) · Japan (1)
Robert Coleman (2) · Allan L Covens (1) · Amit M Oza (1) · D. McMeekin (1) · David Bender (1) · David S Miller (1) · David Tait (1) · Don Dizon (1) · Edward W Wang (1) · Floor Backes, MD (1) · Gerardo Colon-Otero (1) · Gini F Fleming (1) · Gini Fleming (1) · Henry Pitot (1) · Israel Zighelboim (1)
PMID 24882554, PMID 25312396, PMID 25318437, PMID 25488966, PMID 25887099, PMID 25937529, PMID 26554651, PMID 31714586, PMID 32379297, PMID 33078978, PMID 33109627, PMID 34224438, PMID 35357903, PMID 37702588, PMID 40132910
U10CA027469 (18), U10CA180868 (12), N01CM00032 (2), N01CM62201 (2), N01CM62203 (2), N01CM62209 (2), P30CA015083 (2), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM17107 (1), N01CM62204 (1)